JPH07116211B2 - Uracil derivative - Google Patents

Uracil derivative

Info

Publication number
JPH07116211B2
JPH07116211B2 JP15223988A JP15223988A JPH07116211B2 JP H07116211 B2 JPH07116211 B2 JP H07116211B2 JP 15223988 A JP15223988 A JP 15223988A JP 15223988 A JP15223988 A JP 15223988A JP H07116211 B2 JPH07116211 B2 JP H07116211B2
Authority
JP
Japan
Prior art keywords
formula
compound
reaction
ethyluracil
above formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP15223988A
Other languages
Japanese (ja)
Other versions
JPH01319496A (en
Inventor
煕 目黒
洋 大類
藤田  明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
T Hasegawa Co Ltd
Original Assignee
T Hasegawa Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by T Hasegawa Co Ltd filed Critical T Hasegawa Co Ltd
Priority to JP15223988A priority Critical patent/JPH07116211B2/en
Publication of JPH01319496A publication Critical patent/JPH01319496A/en
Publication of JPH07116211B2 publication Critical patent/JPH07116211B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Description

【発明の詳細な説明】 (産業上の利用分野) 本発明は、エイズの治療薬として使用されている1−
(2−デオキシ−3−アジド−β−D−リボフラノシ
ル)−5−エチルウラシル(以下CS-85と言う)の合成
中間体として有用な従来の文献に未載の新規化合物及び
該化合物の新規な製法に関する。
DETAILED DESCRIPTION OF THE INVENTION (Field of Industrial Application) The present invention is used as a therapeutic agent for AIDS.
(2-deoxy-3-azido-β-D-ribofuranosyl) -5-ethyluracil (hereinafter referred to as CS-85) useful as a synthetic intermediate, a novel compound which has not been described in conventional literature and a novel compound of the compound Regarding manufacturing method.

更に詳しくは、本発明は、エイズの治療薬として使用さ
れている下記式(A) で表されるCS-85の合成の際の中間体として有用な新規
な下記式(1) 式中、R1は水素原子、水酸基又は を示す で表されるウラシル誘導体に関する。
More specifically, the present invention provides the following formula (A) used as a therapeutic agent for AIDS. A novel formula (1) useful as an intermediate in the synthesis of CS-85 represented by In the formula, R1 is a hydrogen atom, a hydroxyl group or The present invention relates to a uracil derivative represented by.

(従来の技術) 従来、上記式(A)のCS-85を合成する方法としては、
例えば5−エチルウラシルを原料とし、該化合物を無水
酢酸と反応させN−1−アセチル−5−エチルウラシル
を合成し、該化合物を酢酸第二水銀で処理してN−1−
アセチル−5−エチルウラシルのモノ水銀塩となし、次
いで該水銀塩を3,5一ジ−0−(p−クロロベンゾイ
ル)−2−デオキシ−α,β一D−リボフラノシルクロ
ライドと反応させ1−[3,5−ジ−0−(p−クロロベ
ンゾイル)−2−デオキシ−α,β−D−リボフラノシ
ル]−5−エチルウラシルを形成せしめ、次にこのウラ
シルを塩基性のカラムクロマトグラフィ−で脱ベンゾイ
ル化して2−デオキシ−α,β−D−リボフラノシル−
5−エチルウラシルな形成させ、更に、該ウラシルをベ
ンゾイルクロライドと反応させ、5一0−ベンゾイル−
5−エチル−2−デオキシウリジンを合成し、該ウリジ
ンをメシルクロライドで処理した後ソジウムアジドと反
応させ、その後酢酸で加水分解して該式(A)の化合物
を得る方法が知られている(J.Med.Chem.1969,12,533〜
534及びJ.Med.Chem.1987,30,1270〜1278参照)。
(Prior Art) Conventionally, as a method for synthesizing CS-85 of the above formula (A),
For example, using 5-ethyluracil as a starting material, the compound is reacted with acetic anhydride to synthesize N-1-acetyl-5-ethyluracil, and the compound is treated with mercuric acetate to prepare N-1-
Acetyl-5-ethyluracil monomercury salt, which was then reacted with 3,5 1-di-0- (p-chlorobenzoyl) -2-deoxy-α, β-D-ribofuranosyl chloride. 1- [3,5-di-0- (p-chlorobenzoyl) -2-deoxy-α, β-D-ribofuranosyl] -5-ethyluracil was formed and then this uracil was subjected to basic column chromatography. Debenzoylation with 2-deoxy-α, β-D-ribofuranosyl-
5-ethyluracil is formed and the uracil is further reacted with benzoyl chloride to give 5-10-benzoyl-
A method is known in which 5-ethyl-2-deoxyuridine is synthesized, treated with mesyl chloride, reacted with sodium azide, and then hydrolyzed with acetic acid to obtain the compound of the formula (A) (J .Med.Chem.1969,12,533〜
534 and J. Med. Chem. 1987, 30, 1270-1278).

しかしながら、上記の方法は、反応の工程が長く、しか
も収率が低いという不利益があり、実用的な方法とは言
いがたい。従って、短い工程で且つ好収率に前記式
(A)の化合物を製造する方法の開発が強く望まれてい
る。
However, the above method is disadvantageous in that the reaction step is long and the yield is low, and it cannot be said to be a practical method. Therefore, development of a method for producing the compound of the formula (A) in a short process and in good yield is strongly desired.

(発明が解決しようとする課題) 本発明の目的は、エイズの治療薬として有用な上記式
(A)の化合物を合成するに際し、上記従来の提案と異
なり、短い製造工程でしかも好収率で前記式(A)の化
合物を合成するのに有用な上記式(1)の新規中間体及
びその製造方法を提供することにある。
(Problems to be Solved by the Invention) An object of the present invention is to synthesize a compound of the above formula (A) useful as a therapeutic agent for AIDS, unlike the above-mentioned conventional proposals, in a short production process and in a good yield. It is an object of the present invention to provide a novel intermediate of the above formula (1) useful for synthesizing the compound of the above formula (A) and a method for producing the same.

(課題を解決するための手段) 本発明者らは、上述の従来方法における不利益乃至欠点
を解消すべくCS-85の合成について鋭意研究を行ってき
た。その結果、市場で安価且つ容易に入手できるキシロ
ースから容易に合成もしくは入手できるテトラアセチル
キシロフラノース[下記式(5)]から合成することの
できる本発明の上記式(1)の従来の文献未載の化合物
を使用すれば、上記式(A)の化合物が好純度且つ好収
率でしかも工業的に簡単な操作で有利に合成できること
を見出し本発明を完成した。
(Means for Solving the Problems) The present inventors have earnestly studied synthesis of CS-85 in order to solve the above-mentioned disadvantages and drawbacks of the conventional method. As a result, conventional literatures of the above formula (1) of the present invention, which can be synthesized from tetraacetyl xylofuranose [formula (5) below] which can be easily synthesized or obtained from xylose which is inexpensive and easily available on the market, have not been published. The present invention has been completed by finding that the compound of the formula (A) can be advantageously synthesized with a high purity and a high yield and by an industrially simple operation by using the compound of the formula (1).

しかして、本発明によれば、 (a) 下記式(5) 式中、Acはアセチル基を示す(以下同様)、で表される
テトラアセチルキシロフラノースを、例えば無水塩化第
二錫の存在下に有機溶媒中で、下記式(4) 式中、Meはメチル基を示す(以下同様)、で表される5
−エチルビス(トリメチルシリル)ウラシルと反応させ
て下記式(3) で表される1−(2,3,5−トリ−O−アセチルキシロフ
ラノシル)−5−エチルウラシルを形成させ、 (b) 式(3)の化合物の塩基の存在下に加水分解し
て下記式(2) で表される1−β−D−キシロフラノシル−5−エチル
ウラシルを合成し、 (c) 式(2)の化合物を酸の存在下にアセトンと反
応させることにより、上記式(A)の化合物の合成中間
体として有用な本発明の前記式(1)に包含される下記
式(1)−3 で表される1−(3,5−0−イソプロピリデン−β−D
−キシロフラノシル)−5−エチルウラシルを合成し、 (d) 式(1)−3の化合物をアセトニトリル中でク
ロロチオノ炭酸フエニル及び4−ジメチルアミノピリジ
ンの存在下に反応させることにより、上記式(A)の化
合物の合成中間体として有用な本発明の式(1)に包含
される下記式(1)−2 で表される1−(2−0−フエノキシチオカルボニル−
3,5−0−イソプロピリデン−β−D−キシロフラノシ
ル)−5−エチルウラシルを合成し、 (e) 上記式(1)−2の化合物を有機溶媒中でn−
トリブチルチンヒドライド及びアゾビスイソブチロニト
リルの存在下に反応させることにより、上記式(A)の
化合物の合成中間体として有用な本発明の式(1)に包
含される下記式(1)−1 で表される1−(2−デオキシ−3,5−O−イソプロピ
リデン−β−D−キシロフラノシル)−5−エチルウラ
シルを合成し、 (f) 次いで、上記式(1)−1の化合物を溶媒中で
酸の存在下に加水分解させることにより下記式(D) で表される1−(2−デオキシ−β−D−キシロフラノ
シル)−5−エチルウラシルを合成し、 (g) 上記式(D)の化合物を有機溶媒中でベンゾイ
ルハロゲン化物と反応させることにより、上記式(A)
の化合物の合成中間体として有用な下記式(C) 式中、Bzはべンゾイル基を示す(以下同様)で表される
1−(2−デオキシ−5−ベンゾイル−β,D−キシロフ
ラノシル)−5−エチルウラシルを合成し、 (h) 上記式(C)の化合物を有機溶媒中でメシチル
ハロゲン化物と反応させ、次いで、溶媒の存在下にソジ
ウムアジドと反応することにより上記式(A)の合成中
間体として有用な下記式(B) で表される1−(2−デオキシ−3−アジド−5−ベン
ゾイル−β,D−リボフラノシル)−5−エチルウラシル
を合成することができる。
Then, according to the present invention, (a) the following formula (5) In the formula, Ac represents an acetyl group (the same applies hereinafter), tetraacetyl xylofuranose represented by the following formula (4) in an organic solvent in the presence of anhydrous stannic chloride: In the formula, Me represents a methyl group (the same applies hereinafter), represented by 5
-Ethylbis (trimethylsilyl) uracil reacted with the following formula (3) 1- (2,3,5-tri-O-acetylxylofuranosyl) -5-ethyluracil represented by the formula (b) is hydrolyzed in the presence of a base of the compound of the formula (3). Formula (2) below By synthesizing 1-β-D-xylofuranosyl-5-ethyluracil represented by: (c) reacting the compound of formula (2) with acetone in the presence of an acid to give a compound of formula (A) above. The following formula (1) -3 included in the above formula (1) of the present invention which is useful as a synthetic intermediate: 1- (3,5-0-isopropylidene-β-D represented by
-Xylofuranosyl) -5-ethyluracil is synthesized, and (d) the compound of formula (1) -3 is reacted in acetonitrile in the presence of phenyl chlorothionocarbonate and 4-dimethylaminopyridine to give the above formula (A). The following formula (1) -2 included in the formula (1) of the present invention, which is useful as a synthetic intermediate for the compound of 1- (2-0-phenoxythiocarbonyl-represented by
3,5-0-isopropylidene-β-D-xylofuranosyl) -5-ethyluracil was synthesized, and (e) the compound of the formula (1) -2 was n-
By reacting in the presence of tributyltin hydride and azobisisobutyronitrile, the following formula (1) included in the formula (1) of the present invention, which is useful as a synthetic intermediate for the compound of the above formula (A), -1 1- (2-deoxy-3,5-O-isopropylidene-β-D-xylofuranosyl) -5-ethyluracil represented by the following formula (f), and then the compound of the formula (1) -1 By hydrolyzing in the presence of an acid in a solvent, the following formula (D) By synthesizing 1- (2-deoxy-β-D-xylofuranosyl) -5-ethyluracil represented by: (g) by reacting the compound of the formula (D) with benzoyl halide in an organic solvent, The above formula (A)
Of the following formula (C) useful as a synthetic intermediate for the compound of In the formula, Bz represents a benzoyl group (the same applies hereinafter), and 1- (2-deoxy-5-benzoyl-β, D-xylofuranosyl) -5-ethyluracil is synthesized, and (h) the above formula ( A compound of the formula (B) useful as a synthetic intermediate of the above formula (A) by reacting the compound of C) with a mesityl halide in an organic solvent and then reacting with sodium azide in the presence of a solvent. 1- (2-deoxy-3-azido-5-benzoyl-β, D-ribofuranosyl) -5-ethyluracil represented by can be synthesized.

更に、上記式(B)の化合物をメタノールなどの有機溶
媒中でソジウムメチラートなどの塩基と反応させること
により、式(A)の化合物を容易に合成することができ
る。
Further, the compound of formula (A) can be easily synthesized by reacting the compound of formula (B) with a base such as sodium methylate in an organic solvent such as methanol.

前記式(D)の化合物から前記式(A)の化合物の製造
工程を含めて、前記式(5)の化合物から本発明の式
(1)の化合物を製造する方法を反応式で示すと、例え
ば下記のとおりである。
A reaction scheme shows a method for producing the compound of formula (1) of the present invention from the compound of formula (5), including the step of producing the compound of formula (A) from the compound of formula (D), For example:

前記式(A)のCS-85の合成中間体として有用な本発明
の上記式(1)の化合物の製造方法を、上記反応式Iに
従って以下にさらに詳細に説明する。
The method for producing the compound of the above formula (1) of the present invention, which is useful as a synthetic intermediate of CS-85 of the above formula (A), will be described in more detail below according to the above reaction scheme I.

まず工程(a)における上記式(5)の化合物から上記
式(3)の化合物を合成する反応は、式(5)の化合物
を有機溶媒中、無水塩化第二錫の存在下に上記式(4)
の5−エチルビス(トリメチルシリル)ウラシルと反応
させることにより容易に行うことができる。
First, in the reaction for synthesizing the compound of the above formula (3) from the compound of the above formula (5) in the step (a), the compound of the above formula (5) is added in the presence of anhydrous stannic chloride in an organic solvent. 4)
It can be easily carried out by reacting with 5-ethylbis (trimethylsilyl) uracil.

上記反応は採用する有機溶媒の種類によっても異なる
が、一般的には、約0℃〜50℃程度の温度範囲で、約1
〜10時間程度で行うことができる。
Although the above reaction varies depending on the type of organic solvent used, it is generally about 1 ° C in the temperature range of about 0 ° C to 50 ° C.
It can be done in about 10 hours.

上記反応に使用する上記式(4)の5−エチルビス(ト
リメチルシリル)ウラシルの使用量には特別の制約はな
いが、通常上記式(5)の化合物1モルに対して、例え
ば、約1〜約1.5モル程度の範囲で用いられる。また、
触媒として使用される無水塩化第二錫の使用量も広い範
囲で変えることができるが、一般的は、例えば、上記式
(5)の化合物1モルに対して約1〜約1.5モル程度の
範囲が適当である。さらに、使用しうる有機溶媒は、反
応に対して不活性な溶媒であれば特に制約はなくいずれ
であってもよいが、通常はべンゼン、トルエン、1,2−
ジクロルエタン、ジクロルメタン、四塩化炭素などがし
ばしば使用される。これら溶媒の使用量は適宜に選択す
ることができ、例えば、式(5)の化合物に対して約5
〜約50重量倍程度の使用量を好ましく挙げることができ
る。反応終了後は、常法に従って生成物を中和、洗浄
し、所望により例えば、カラムクロマトグラフイーのご
とき手段で精製して前記式(3)の化合物が得られる。
There is no particular limitation on the amount of 5-ethylbis (trimethylsilyl) uracil of the above formula (4) used in the above reaction, but it is usually about 1 to about 1 mol per 1 mol of the compound of the above formula (5). It is used in the range of about 1.5 mol. Also,
The amount of anhydrous stannic chloride used as a catalyst can be varied within a wide range, but generally, it is, for example, in the range of about 1 to about 1.5 mol per 1 mol of the compound of the above formula (5). Is appropriate. Further, the organic solvent that can be used is not particularly limited as long as it is a solvent inert to the reaction, but it is usually benzene, toluene, 1,2-
Dichloroethane, dichloromethane, carbon tetrachloride, etc. are often used. The amount of these solvents to be used can be appropriately selected, and for example, is about 5 with respect to the compound of the formula (5).
The preferable amount is about 50 times by weight. After completion of the reaction, the product is neutralized and washed according to a conventional method and, if desired, purified by a means such as column chromatography to obtain the compound of the formula (3).

次に工程(b)において、上記式(3)の化合物から上
記式(2)の化合物を合成するには、例えば、式(3)
の化合物をナトリウムエチラート、ナトリウムメチラー
トのごとき塩基と反応させることにより容易に行うこと
ができる。この反応に使用する塩基の使用量は触媒量で
充分であるが、その好適な使用量を具体的に示せば、例
えば式(3)の化合物1モルに対して約1/100〜約1/10
モル程度の範囲である。上述の如き塩基を使用する場合
は、反応系内で対応するアルコール類と金属ナトリウム
とから調製してもよい。反応は使用されるアルコールが
還流する程度の温度で行われれる。反応時間は、通常2
時間程度行えば充分である。反応終了後は、例えば酸性
のイオン交換樹脂のごとき酸で中和し、例えば再結晶な
どの手段で精製して式(2)の化合物が好純度、好収率
で得られる。
Next, in the step (b), for synthesizing the compound of the above formula (2) from the compound of the above formula (3), for example, the following formula (3)
This can be easily carried out by reacting the compound of (1) with a base such as sodium ethylate or sodium methylate. Although the amount of the base used in this reaction is a catalytic amount, the suitable amount of the base used is specifically, for example, about 1/100 to about 1/100 mol per 1 mol of the compound of the formula (3). Ten
It is in the range of moles. When a base as described above is used, it may be prepared from the corresponding alcohol and sodium metal in the reaction system. The reaction is carried out at a temperature at which the alcohol used is refluxed. Reaction time is usually 2
It's enough to do it for about a hour. After completion of the reaction, the compound of the formula (2) is obtained in good purity and good yield by neutralizing with an acid such as an acidic ion exchange resin and purifying by means such as recrystallization.

次に工程(c)では、上記式(2)の化合物を酸の存在
下にアセトンと反応させて、本発明の上記式(1)に包
含される上記式(1)−3の1−(3,5−O−イソプロ
ピリデン−β−D−キシロフラノシル)−5−エチルウ
ラシルを合成することができる。反応は室温程度の温度
で約3時間程度行えば充分である。この反応に使用しう
る酸としては、例えばp−トルエンスルホン酸、塩酸、
硫酸などのごとき酸が使用できる。これら酸の使用量は
触媒量程度で充分であり、例えば、上記式(2)の化合
物に対して約1/100重量%程度使用すれば充分である。
また、アセトンの使用量は当モル以上使用すればよく、
例えば、上記式(2)化合物1モルに対して約1〜約10
0モル程度の範囲が好適である。反応終了後は、反応生
成物を水酸化バリウムの如きアルカリで中和し、更に生
成物を再結晶のごとき手段で精製することにより、式
(1)−3の化合物が好純度、好収率で得られれる。
Next, in the step (c), the compound of the above formula (2) is reacted with acetone in the presence of an acid to give 1- (of the above formula (1) -3 included in the above formula (1) of the present invention. 3,5-O-isopropylidene-β-D-xylofuranosyl) -5-ethyluracil can be synthesized. It is sufficient to carry out the reaction at room temperature for about 3 hours. Examples of the acid that can be used in this reaction include p-toluenesulfonic acid, hydrochloric acid,
Acids such as sulfuric acid can be used. A catalytic amount of these acids is sufficient, and for example, about 1/100 wt% of the compound of the above formula (2) is sufficient.
Also, the amount of acetone used may be equimolar or more,
For example, about 1 to about 10 mol per 1 mol of the compound of the formula (2)
A range of about 0 mol is preferable. After the completion of the reaction, the reaction product is neutralized with an alkali such as barium hydroxide, and the product is purified by a means such as recrystallization to give the compound of formula (1) -3 in good purity and good yield. Can be obtained at.

次に工程(d)において、上記式(1)−3の化合物か
ら本発明の上記式(1)に包含される上記式(1)−2
の1−(2−0−フエノキシチオカルボニル−3,5−O
−イソプロピリデシ−β−D−キシロフラノシル)5−
エチルウラシルを合成するには、式(1)−3の化合物
をアセトニトリル中でクロロチオノ炭酸フエニルおよび
4−ジメチルアミノピリジンの存在下に反応させること
により行われる。反応は室温程度の温度で約2〜約4時
間程度で行われる。この反応に使用するクロロチオノ炭
酸フエニルの使用量とレては、例えば、式(1)−3の
化合物に対して約1〜約1.5モル程度の範囲を例示する
ことができる。また、4−ジメチルアミノピリジンは過
剰に用いた方が有利であり、例えば、式(1)−3の化
合物1モルに対して約1.5〜約3モル程度の範囲で使用
するのが一般的である。アセトニトリルの使用量には格
別の制約はなく適宜に選択することができるが、通常は
例えば、式(1)−3の化合物に対して約5〜約100重
量倍の範囲が適当である。反応終了後、例えば酢酸エチ
ルのごとき溶媒で分配抽出し、有機層を塩酸のごとき酸
の水溶液で洗浄し、所望により生成物を再結晶のごとき
手段で精製して本発明の上記式(1)−2が好純度、好
収率で得られる。
Next, in the step (d), the compound of the above formula (1) -2 included in the above formula (1) of the present invention from the compound of the above formula (1) -3.
1- (2-0-phenoxythiocarbonyl-3,5-O
-Isopropylideci-β-D-xylofuranosyl) 5-
The synthesis of ethyluracil is carried out by reacting the compound of formula (1) -3 in acetonitrile in the presence of phenyl chlorothionocarbonate and 4-dimethylaminopyridine. The reaction is carried out at a temperature of about room temperature for about 2 to about 4 hours. The amount of phenyl chlorothionocarbonate used in this reaction may be, for example, about 1 to about 1.5 mol based on the compound of formula (1) -3. Further, it is advantageous to use 4-dimethylaminopyridine in excess, and for example, it is generally used in the range of about 1.5 to about 3 mol per 1 mol of the compound of the formula (1) -3. is there. The amount of acetonitrile used is not particularly limited and may be appropriately selected. Usually, for example, a range of about 5 to about 100 times by weight with respect to the compound of formula (1) -3 is suitable. After completion of the reaction, partition extraction is carried out with a solvent such as ethyl acetate, the organic layer is washed with an aqueous solution of an acid such as hydrochloric acid, and if desired, the product is purified by a means such as recrystallization to obtain the above formula (1) of the present invention. -2 is obtained with good purity and good yield.

次に、工程(e)において、上記式(1)−2の化合物
から本発明の上記式(1)−2の化合物から本発明の上
記式(1)に包含される上記式(1)−1の1−(2−
デオキシ−3,5−O−イソプロピリデン−β−D−キシ
ロフラノシル)−5−エチルウラシルを合成するには、
例えば、上記式(1)−2の化合物を有機溶媒中、n−
トリブチルチンヒドライド及びアゾビスイソブチロニト
リルの存在下に処理して合成される。反応は例えば窒素
ガスのごとき不活性雰囲気下に行うのが有利である。処
理温度は使用される有機溶媒にもよるが、一般的には約
50℃〜約150℃程度の範囲が採用される。処理時間も適
宜に選択することができるが、通常は約2〜約3時間程
度の範囲が選択される。この反応に用いられるn−トリ
ブチルチンヒドライドの使用量としては、式(1)−2
の化合物1モルに対して約2〜約5モル程度の範囲を好
ましく例示することができる。また、アゾビスイソブチ
ロニトリルの好ましい使用量としては、例えば、式
(1)−2の化合物1モルに対して約1/5〜約1/50モル
程度の範囲とすることができる。有機溶媒は種々のもの
が使用可能であるが、好ましい溶媒を示せば例えば、ト
ルエン、キシレン等を挙げることができる。これら溶媒
の使用量には特別の制約はなく適当な範囲を選択するこ
とができ、例えば式(1)−2の化合物に対して約10〜
約200重量倍程度の範囲が例示される。反応終了後、反
応生成物をカラムクロマトグラフイーのごとき手段で精
製するか、又は再結晶のような手段で精製して本発明の
式(1)−1の化合物が好純度、好収率で得られる。
Next, in the step (e), from the compound of the above formula (1) -2 to the compound of the above formula (1) -2 of the present invention, the above formula (1)-included in the above formula (1) of the present invention. 1- (2-
To synthesize deoxy-3,5-O-isopropylidene-β-D-xylofuranosyl) -5-ethyluracil,
For example, the compound of the above formula (1) -2 is n-
It is synthesized by treatment in the presence of tributyltin hydride and azobisisobutyronitrile. The reaction is advantageously carried out under an inert atmosphere such as nitrogen gas. Although the treatment temperature depends on the organic solvent used, it is generally about
A range of about 50 ° C to about 150 ° C is adopted. The treatment time can be appropriately selected, but usually, the range of about 2 to about 3 hours is selected. The amount of n-tributyltin hydride used in this reaction is represented by the formula (1) -2
A preferable range is about 2 to about 5 mol per 1 mol of the compound. The preferred amount of azobisisobutyronitrile used is, for example, in the range of about 1/5 to about 1/50 mol per 1 mol of the compound of formula (1) -2. Although various kinds of organic solvents can be used, examples of preferred solvents include toluene and xylene. There is no particular restriction on the amount of these solvents to be used, and an appropriate range can be selected.
An example is a range of about 200 times by weight. After completion of the reaction, the reaction product is purified by means such as column chromatography, or by means such as recrystallization to obtain the compound of formula (1) -1 of the present invention in good purity and good yield. can get.

次に、工程(f)では、上記式(1)−1の化合物を酸
と反応させて、上記式(D)の1−(2−デオキシ−
β,D−キシロフラノシル)−5−エチルウラシルを合成
することができる。反応は約0〜約80℃程度の温度で約
1〜約5時間程度の時間で十分である。この反応に使用
しうる酸としては、例えば、p−トルエンスルホン酸、
酢酸、塩酸、硫酸等の如き酸が挙げられる。これらの酸
の使用量は、例えば、上記式(1)−1の化合物1モル
に対して約0.1〜約200モル程度の範囲が好適である。反
応終了後、抽出、蒸留、更には、シリカゲルカラムクロ
マトグラフィーなどの手段で精製することにより、上記
式(D)の化合物が好純度、好収率で得られる。
Next, in the step (f), the compound of the above formula (1) -1 is reacted with an acid to give 1- (2-deoxy-of the above formula (D).
β, D-xylofuranosyl) -5-ethyluracil can be synthesized. For the reaction, a temperature of about 0 to about 80 ° C. and a time of about 1 to about 5 hours are sufficient. Examples of the acid that can be used in this reaction include p-toluenesulfonic acid,
Acids such as acetic acid, hydrochloric acid, sulfuric acid and the like can be mentioned. The amount of these acids used is preferably in the range of, for example, about 0.1 to about 200 mol per 1 mol of the compound of the formula (1) -1. After completion of the reaction, the compound of the above formula (D) is obtained in good purity and good yield by extraction, distillation, and further purification by means such as silica gel column chromatography.

次に工程(g)において、上記式(D)の化合物から上
記式(C)の1−(2−デオキシ−5−ベンゾイル−
β,D−キシロフラノシル)−5−エチルウラシルを合成
するには、式(D)の化合物を有機溶媒中でベンゾイル
クロライドと反応させることにより行われる。反応は約
0℃〜約50℃程度の温度で約0.5時間〜約5時間程度の
時間行うことができる。この反応に使用するベンゾイル
クロライドの使用量としては、例えば、式(D)の化合
物1モルに対して約1.0〜約1.5モル程度の範囲を例示す
ることができる。また、上記反応に使用する有機溶媒の
例としては、例えば、ピリジン、ジクロルメタンなどを
挙げることができ、その使用量は、例えば、上記式
(D)の化合物に対して約5〜約20重量倍程度の使用量
を好ましく挙げることができる。反応終了後は抽出、減
圧蒸留、シリカゲルカラムクロマトグラフィーなどの精
製手段で用いて上記式(C)の化合物を好純度、好収率
で得ることができる。
Next, in the step (g), 1- (2-deoxy-5-benzoyl-) of the above formula (C) is converted from the compound of the above formula (D).
The synthesis of β, D-xylofuranosyl) -5-ethyluracil is carried out by reacting the compound of formula (D) with benzoyl chloride in an organic solvent. The reaction can be carried out at a temperature of about 0 ° C. to about 50 ° C. for about 0.5 hours to about 5 hours. The amount of benzoyl chloride used in this reaction can be, for example, in the range of about 1.0 to about 1.5 mol per mol of the compound of the formula (D). In addition, examples of the organic solvent used in the above reaction include pyridine and dichloromethane, and the amount thereof is, for example, about 5 to about 20 times the weight of the compound of the above formula (D). The amount of use can be preferably mentioned. After completion of the reaction, the compound of the formula (C) can be obtained in good purity and good yield by using a purification means such as extraction, distillation under reduced pressure, silica gel column chromatography and the like.

次に工程(h)において、上記式(C)の化合物から上
記式(B)の1−(2−デオキシ−3−アジド−5−ベ
ンゾイル−β,D−リボフラノシル)−5−エチルウラシ
ルを合成するには、式(C)の化合物を有機溶媒中でメ
シルクロライドと反応させることにより、メシル化物で
ある1−(2−デオキシ−3−メシル−5−ベンゾイル
−β,D−キシロフラノシル)−5−エチルウラシルを合
成し、次いで該メシル化物を溶媒中ソジウムアジドと反
応させてアジド化することにより容易に行われる。上記
メシル化反応は約0〜約50℃程度の温度で約1〜約5時
間程度の時間行うことができる。この反応に使用するメ
シルクロライドの使用量としては、式(C)の化合物に
対して約1〜約5モル程度の範囲を例示することができ
る。また、上記反応に使用する有機溶媒は、通常ピリジ
ン、ジクロルメタンなどが例示できる。これらの溶媒の
使用量は、適宜に選択すればよく、例えば、式(C)の
化合物に対して約1〜約30重量倍程度の使用量を好まし
く挙げることができる。反応終了後、溶媒を除去し、精
製単離することなく、そのまま次のアジド化反応に進め
ることができる。該アジド化反応は約25〜約100℃程度
の温度で約0.5〜約5時間程度の時間行うことができ
る。上記反応に使用するソジウムアジドの使用量は、例
えば、上記式(C)の化合物1モルに対して約1〜約5
モル程度であることができる。また、上記反応には種々
の溶媒が使用可能であるが、例えば、ジメチルホルムア
ミド、ジメチルスルホキシドなどを挙げることができ
る。これらの溶媒の使用量には、特別な制約はなく、例
えば、式(C)の化合物に対して約1〜約50重量倍程度
の範囲とすることができる。反応終了後、抽出、蒸留、
更にはシリカゲルカラムクロマトグラフィーなどの精製
手段を用いて上記式(B)の化合物を好純度、好収率で
得られる。
Next, in step (h), 1- (2-deoxy-3-azido-5-benzoyl-β, D-ribofuranosyl) -5-ethyluracil of the above formula (B) is synthesized from the compound of the above formula (C). To do this, the compound of formula (C) is reacted with mesyl chloride in an organic solvent to give a mesylated product, 1- (2-deoxy-3-mesyl-5-benzoyl-β, D-xylofuranosyl) -5. -Easily done by synthesizing ethyluracil and then reacting the mesylated product with sodium azide in a solvent to azide. The mesylation reaction can be carried out at a temperature of about 0 to about 50 ° C. for a time of about 1 to about 5 hours. The amount of mesyl chloride used in this reaction may be in the range of about 1 to about 5 mol based on the compound of formula (C). Further, the organic solvent used in the above reaction can be typically exemplified by pyridine and dichloromethane. The amount of these solvents used may be appropriately selected, and for example, the amount of about 1 to about 30 times by weight the amount of the compound of the formula (C) can be preferably mentioned. After completion of the reaction, the solvent can be removed and the reaction can be directly proceeded to the next azidation reaction without purification and isolation. The azidation reaction can be carried out at a temperature of about 25 to about 100 ° C. for a time of about 0.5 to about 5 hours. The amount of sodium azide used in the above reaction is, for example, about 1 to about 5 per 1 mol of the compound of the above formula (C).
It can be on the order of moles. Further, various solvents can be used in the above reaction, and examples thereof include dimethylformamide and dimethylsulfoxide. The amount of these solvents used is not particularly limited and can be, for example, in the range of about 1 to about 50 times by weight the amount of the compound of the formula (C). After completion of the reaction, extraction, distillation,
Further, the compound of the above formula (B) can be obtained in good purity and good yield by using a purification means such as silica gel column chromatography.

以上述べた如くして製造される前記式(B)の化合物
は、例えば前記反応式に示したようにして、エイズの治
療薬として使用できるCS-85に誘導することができる。
The compound of formula (B) produced as described above can be derivatized into CS-85 which can be used as a therapeutic agent for AIDS, for example, as shown in the above reaction formula.

本発明の上記式(B)の化合物からCS-85を合成するに
は、例えば、式(B)の化合物をメタノールなどの溶媒
中、例えば、ソジウムメチラートなどの塩基と反応させ
ることにより容易に行うことができる。
CS-85 can be easily synthesized from the compound of the above formula (B) of the present invention by reacting the compound of the formula (B) with a base such as sodium methylate in a solvent such as methanol. Can be done.

(実施例及び参考例) 以下に本発明の式(1)及びCS-85の化合物の製造方法
を実施例ならびに参考例を挙げてさらに説明する。
(Examples and Reference Examples) The method for producing the compound of formula (1) and CS-85 of the present invention will be further described below with reference to Examples and Reference Examples.

実施例1 1−(2,3,5−トリ−O−アセチルキシロフラノシル)
−5−エチルウラシル[式(3)]の合成[工程
(a)] フラスコにテトラアセチルキシロフラノース16.3g(51.
1ミリモル)、5−エチルビス(トリメチルシリル)ウ
ラシル16g(56.2ミリモル)および1,2−ジクロルエタン
500mlを仕込み、室温下で撹拌しながら溶解させ、この
中に1,2−ジクロルエタン60mlに無水塩化第二錫14.2g
(54.4ミリモル)を溶解した溶液を30分間で滴下しなが
ら加え、滴下終了後、更に同じ温度で約10時間反応させ
た。反応終了後、反応液にクロロホルム200mlを加え、
飽和炭酸ナトリウム水溶液で洗浄し、濾液を硫酸ナトリ
ウムで乾燥した後、減圧濃縮し、シリカゲルカラムクロ
マトグラフイー(クロロホルム:メタノール=9:1)に
かけて精製して標記化合物を19.7g得た。
Example 1 1- (2,3,5-tri-O-acetylxylofuranosyl)
Synthesis of 5-ethyluracil [Formula (3)] [Step (a)] 16.3 g of tetraacetyl xylofuranose (51.
1 mmol), 16 g (56.2 mmol) of 5-ethylbis (trimethylsilyl) uracil and 1,2-dichloroethane
Charge 500 ml, dissolve with stirring at room temperature, and in this, 1,2-dichloroethane 60 ml, anhydrous stannic chloride 14.2 g
A solution in which (54.4 mmol) was dissolved was added dropwise over 30 minutes, and after the addition was completed, the reaction was continued at the same temperature for about 10 hours. After completion of the reaction, add 200 ml of chloroform to the reaction solution,
The extract was washed with saturated aqueous sodium carbonate solution, dried over sodium sulfate, concentrated under reduced pressure, and purified by silica gel column chromatography (chloroform: methanol = 9: 1) to obtain 19.7 g of the title compound.

収率:99.6%1 H-NMR(CDCl3) δppm:1.16(3H,t,J=7.5Hz),2.11(3H,S),2.14(6H,
S),2.40(2H,q,J=7.5Hz),4.32〜4.6(2H,m),5.15〜
5.17(1H,m),5.21〜5.40(1H,m),6.09(1H,d,J=2.9H
z),7.26(1H,br,S),9.46(1H,brS) 実施例2 1−β−D−キシロフラノシル−5−エチルウラシル
[式(2)]の合成[工程(b)] フラスコに式(3)の1−(2,3,5−トリ−O−アセチ
ルキシロフラノシル)−5−エチルウラシル18g(46.6
ミリモル)及び無水メタノール500mlを仕込み、溶解さ
せた後、室温下で、金属ナトリウムの細片を触媒量加え
2時間還流した。反応終了後、イオン交換樹脂(Amberl
ist15)で中和してから濾過し、濾液を濃縮し、濃縮液
にエチルアルコール:エーテル(1:1)を加え再結晶を
行って、標記化合物を11.95g得た。
Yield: 99.6% 1 H-NMR (CDCl 3 ) δppm: 1.16 (3H, t, J = 7.5Hz), 2.11 (3H, S), 2.14 (6H,
S), 2.40 (2H, q, J = 7.5Hz), 4.32 ~ 4.6 (2H, m), 5.15 ~
5.17 (1H, m), 5.21 to 5.40 (1H, m), 6.09 (1H, d, J = 2.9H
z), 7.26 (1H, br, S), 9.46 (1H, brS) Example 2 Synthesis of 1-β-D-xylofuranosyl-5-ethyluracil [Formula (2)] [Step (b)] Formulation in flask 18 g of 1- (2,3,5-tri-O-acetylxylofuranosyl) -5-ethyluracil of (3) (46.6
(Mmol) and 500 ml of anhydrous methanol were charged and dissolved, and at room temperature, a catalytic amount of metal sodium particles was added and the mixture was refluxed for 2 hours. After the reaction is completed, the ion exchange resin (Amberl
It was neutralized with ist15) and then filtered, the filtrate was concentrated, and ethyl alcohol: ether (1: 1) was added to the concentrated solution for recrystallization to obtain 11.95 g of the title compound.

収率:94.2% 融点:128℃ 実施例3 1−(3,5−O−イソプロピリデン−β−D−キシロフ
ラノシル)−5−エチルウラシル[式(1)−3]の合
成[工程(c)] フラスコに式(2)の1−β−D−キシロフラノシル−
5−エチルウラシル11.95g(43.9ミリモル)、アセトン
300mlおよびp−トルエンスルホン酸1.0gを仕込み、室
温で2時間撹拌した。反応終了後、水酸化バリウム3gで
中和し、濾過した後濃縮した。残さは500gのシリカゲル
を充填したカラムクロマトグラフィー(クロロホルム:
メタノール=9:1)で精製して標記の化合物10.69gを得
た。
Yield: 94.2% Melting point: 128 ° C. Example 3 Synthesis of 1- (3,5-O-isopropylidene-β-D-xylofuranosyl) -5-ethyluracil [formula (1) -3] [step (c)] ] In a flask, 1-β-D-xylofuranosyl-of the formula (2)-
11.95 g (43.9 mmol) of 5-ethyluracil, acetone
300 ml and 1.0 g of p-toluenesulfonic acid were charged, and the mixture was stirred at room temperature for 2 hours. After completion of the reaction, the mixture was neutralized with 3 g of barium hydroxide, filtered and concentrated. The residue was column chromatographed with 500 g of silica gel (chloroform:
Purification with methanol = 9: 1) gave 10.69 g of the title compound.

収率:73.5%1 H-NMR(CDCl3) δppm:1.15(3H,t,J=7.5Hz),1.27(3H,S),1.40(2H,
q,J=7.5Hz),1.48(3H,S),4.07〜4.61(5H,m),6.0
(1H,m),7.96(1H,br,S),10.70(1H,brS) 実施例4 1−(2−O−フェノキシチオカルボニル−3,5−O−
イソプロピリデン−β−D−キシロフラノシル)−5−
エチルウラシル[式(1)−2]の合成[工程(d)] 式(1)−3の1−(3,5−O−イソプロピリデン−β
−D−キシロフラノシル)−5−エチルウラシル4.15g
(13.3ミリモル)を無水アセトニトリル500ml中に撹拌
しながら加え、さらにクロロチオノ炭酸フエニル2.5g
(14.6ミリモル)と4−ジメチルアミノピリジン3.3g
(26.6ミリモル)を加えてから、室温で2時間撹拌し
た。反応終了後、酢酸エチル250ml+水250mlで分配抽出
し、有機層を十分冷却してから1N冷HCl/H2O、飽和炭酸
ナトリウム水溶液、飽和食塩水溶液で順次洗浄を行っ
た。硫酸ナトリウムを加え、一晩放置した後、濾過し、
濃縮して標記化合物を5.42g得た。
Yield: 73.5% 1 H-NMR (CDCl 3 ) δppm: 1.15 (3H, t, J = 7.5Hz), 1.27 (3H, S), 1.40 (2H,
q, J = 7.5Hz), 1.48 (3H, S), 4.07 to 4.61 (5H, m), 6.0
(1H, m), 7.96 (1H, br, S), 10.70 (1H, brS) Example 4 1- (2-O-phenoxythiocarbonyl-3,5-O-
Isopropylidene-β-D-xylofuranosyl) -5-
Synthesis of ethyluracil [formula (1) -2] [step (d)] 1- (3,5-O-isopropylidene-β of formula (1) -3
-D-xylofuranosyl) -5-ethyluracil 4.15 g
(13.3 mmol) was added to 500 ml of anhydrous acetonitrile with stirring, and 2.5 g of phenyl chlorothionocarbonate was added.
(14.6 mmol) and 4-dimethylaminopyridine 3.3 g
(26.6 mmol) was added, and the mixture was stirred at room temperature for 2 hours. After completion of the reaction, the mixture was partitioned and extracted with 250 ml of ethyl acetate + 250 ml of water, the organic layer was sufficiently cooled, and then washed successively with 1N cold HCl / H 2 O, saturated aqueous sodium carbonate solution and saturated saline solution. Sodium sulfate was added and left overnight, then filtered,
Concentration gave 5.42 g of the title compound.

収率:90.9%1 H-NMR(CDCl3) δppm:1.17(3H,t,J=7.5Hz),1.42(3H,S),1.49(3H,
S),2.31(2H,q,J=7.5Hz),4.12〜4.20(3H,m),4.59
(1H,d,J=7.5Hz),5.56(1H,br,S),6.22(1H,brS),
7.10〜7.49(5H,m),7.82(1H,brS),10.03(1H,br
S)。
Yield: 90.9% 1 H-NMR (CDCl 3 ) δppm: 1.17 (3H, t, J = 7.5Hz), 1.42 (3H, S), 1.49 (3H,
S), 2.31 (2H, q, J = 7.5Hz), 4.12 ~ 4.20 (3H, m), 4.59
(1H, d, J = 7.5Hz), 5.56 (1H, br, S), 6.22 (1H, brS),
7.10 ~ 7.49 (5H, m), 7.82 (1H, brS), 10.03 (1H, br
S).

実施例5 1−(2−デオキシ−3,5−O−イソプロピリデン−β
−D−キシロフラノシル)−5−エチルウラシル[式
(1)−1]の合成[工程(e)] デシケーターで減圧乾燥した式(1)−2の1−(2−
O−フェノキシチオカルボニル−3,5−O−イソプロピ
リデン−β−D−キシロフラノシル)−5−エチルウラ
シル4.42g(10.8ミリモル)に蒸留トルエン580mlを加え
て溶解し、アゾビスイソブチロニトリル321mg(2.0ミリ
モル)とn−トリブチルチンヒドライド8.5g(29.2ミリ
モル)を加えた。5時間窒素ガス気流下に75℃に加熱し
還流した。反応終了後、濃縮し、残さをシリカゲルカラ
ムクロマトグラフイー(クロロホルム:酢酸エチル=1:
1)にかけ精製して標記化合物を2.83g得た。
Example 5 1- (2-deoxy-3,5-O-isopropylidene-β
Synthesis of -D-xylofuranosyl) -5-ethyluracil [formula (1) -1] [step (e)] 1- (2- of formula (1) -2 dried under reduced pressure with a desiccator.
O-phenoxythiocarbonyl-3,5-O-isopropylidene-β-D-xylofuranosyl) -5-ethyluracil (4.42 g (10.8 mmol)) was dissolved by adding 580 ml of distilled toluene to 321 mg of azobisisobutyronitrile ( 2.0 mmol) and 8.5 g (29.2 mmol) of n-tributyltin hydride were added. The mixture was heated to 75 ° C. under a nitrogen gas stream for 5 hours and refluxed. After completion of the reaction, the mixture was concentrated, and the residue was subjected to silica gel column chromatography (chloroform: ethyl acetate = 1: 1).
Purification was performed by 1) to obtain 2.83 g of the title compound.

収率:88.4%1 H-NMR(CDCl3) δppm:1.16(3H,t,J=7.5Hz),1.38(3H,S),1.48(3H,
S),2.09〜2.80( H,m),3.84(1H,m),4.1〜4.3(2H,
m),4.3〜4.5(1H,m),6.17(1H,dd,J=5.9Hz),7.93
(1H,brS),9.6(1H,brS)。
Yield: 88.4% 1 H-NMR (CDCl 3 ) δppm: 1.16 (3H, t, J = 7.5Hz), 1.38 (3H, S), 1.48 (3H,
S), 2.09 to 2.80 (H, m), 3.84 (1H, m), 4.1 to 4.3 (2H,
m), 4.3 to 4.5 (1H, m), 6.17 (1H, dd, J = 5.9Hz), 7.93
(1H, brS), 9.6 (1H, brS).

参考例1 1−(2−デオキシ−β,D−キシロフラノシル)−5−
エチルウラシル[式(D)]の合成[工程(f)] フラスコに式(1)−1の1−(2−デオキシ−3,5−
O−イソプロピリデン−β−D−キシロフラノシル)−
5−エチルウラシル2.0g(6.7ミリモル)および70%の
酢酸水溶液67mlを仕込み、50℃の温度で撹拌しながら2.
5時間反応を行った。反応終了後、減圧下に濃縮し、残
さをシリカゲルカラムクロマトグラフィー(クロロホル
ム:メタノール=4:1)にかけ精製し、標記化合物を1.2
1gを得た。
Reference Example 1 1- (2-deoxy-β, D-xylofuranosyl) -5-
Synthesis of Ethyluracil [Formula (D)] [Step (f)] 1- (2-deoxy-3,5-
O-isopropylidene-β-D-xylofuranosyl)-
2.0 g (6.7 mmol) of 5-ethyluracil and 67 ml of 70% acetic acid aqueous solution were charged, and the mixture was stirred at a temperature of 50 ° C. 2.
Reaction was carried out for 5 hours. After completion of the reaction, the reaction mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (chloroform: methanol = 4: 1) to give the title compound (1.2).
I got 1g.

収率:70.0%1 H-NMR(d6-DMSO) δppm:1.05(3H,t,J=7.5Hz),2.04(1H,dd,J=14.7Hz,
2.9Hz),2.14(2H,q,J=7.5Hz),2.4〜2.7(1H,m),3.5
〜3.9(3H,m),4.28(1H,m),4.63(1H,m),5.22(1H,
d,J=2.9Hz),6.11(1H,dd,J=8.2Hz,2.3Hz),7.81(1
H,S),11.12(1H,brS)。
Yield: 70.0% 1 H-NMR (d 6 -DMSO) δppm: 1.05 (3H, t, J = 7.5Hz), 2.04 (1H, dd, J = 14.7Hz,
2.9Hz), 2.14 (2H, q, J = 7.5Hz), 2.4 to 2.7 (1H, m), 3.5
~ 3.9 (3H, m), 4.28 (1H, m), 4.63 (1H, m), 5.22 (1H, m
d, J = 2.9Hz), 6.11 (1H, dd, J = 8.2Hz, 2.3Hz), 7.81 (1
H, S), 11.12 (1H, brS).

参考例2 1−(2−デオキシ−5−ベンゾイル−β,D−キシロフ
ラノシル)−5−エチルウラシル[式(C)]の合成
[工程(g)]。
Reference Example 2 Synthesis of 1- (2-deoxy-5-benzoyl-β, D-xylofuranosyl) -5-ethyluracil [formula (C)] [step (g)].

フラスコに式(D)の1−(2−デオキシ−β,D−キシ
ロフラノシル)−5−エチルウラシル1.0g(3.9ミリモ
ル)およびピリジン20mlを仕込み氷冷で冷却する。この
中に撹拌しながらベンゾイルクロライド0.66g(4.7ミリ
モル)を滴下する。滴下終了後、更に、0℃の温度で2
時間反応を行う。反応終了後、減圧下に濃縮し、残さを
シリカゲルカラムクロマトグラフィー(クロロホルム:
メタノール=95:5)にかけ精製し、標記化合物1.39gを
得た。
A flask is charged with 1.0 g (3.9 mmol) of 1- (2-deoxy-β, D-xylofuranosyl) -5-ethyluracil of the formula (D) and 20 ml of pyridine and cooled with ice. While stirring, 0.66 g (4.7 mmol) of benzoyl chloride was added dropwise thereto. After the dropping is completed, 2 more at a temperature of 0 ° C.
React for time. After the reaction was completed, the reaction mixture was concentrated under reduced pressure, and the residue was subjected to silica gel column chromatography (chloroform:
The product was purified by being applied to methanol = 95: 5) to obtain 1.39 g of the title compound.

収率:99.3%1 H-NMR(CDCl3) δppm:1.11(3H,t,J=7.5Hz),2.31(2H,q,J=7.5Hz),
2.1〜2.8(2H,m),4.2〜4.9(4H,m),5.18(1H,brS),
6.22(1H,dd,J=8.2Hz,2.3Hz),7.23〜8.01(5H,m),8.
58(1H,d,J=3.7Hz),11.0(1H,brS)。
Yield: 99.3% 1 H-NMR (CDCl 3 ) δppm: 1.11 (3H, t, J = 7.5Hz), 2.31 (2H, q, J = 7.5Hz),
2.1 ~ 2.8 (2H, m), 4.2 ~ 4.9 (4H, m), 5.18 (1H, brS),
6.22 (1H, dd, J = 8.2Hz, 2.3Hz), 7.23 ~ 8.01 (5H, m), 8.
58 (1H, d, J = 3.7Hz), 11.0 (1H, brS).

参考例3 1−(2−デオキシ−3−アジド−5−ベンゾイル−β
−D−リボフラノシル)−5−エチルウラシル[式
(B)]の合成[工程(h)]。
Reference Example 3 1- (2-deoxy-3-azido-5-benzoyl-β
Synthesis of -D-ribofuranosyl) -5-ethyluracil [formula (B)] [step (h)].

フラスコに式(C)の1−(2−デオキシ−5−ベンゾ
イル−β−D−キシロフラノシル)−5−エチルウラシ
ル1.3g(3.6ミリモル)およびピリジン30mlを仕込み、
氷水で冷却する。この中に撹拌しながら、メシルクロラ
イド1.24g(10.8ミリモル)を滴下し、更に、0℃で3
時間反応を行う。メシル化反応終了後、蒸留、抽出など
の処理を行い、1−(2−デオキシ−3−メシル−5−
ベンゾイル−β−D−キシロフラノシル)−5−エチル
ウラシル1.98gを得た。
A flask was charged with 1.3 g (3.6 mmol) of 1- (2-deoxy-5-benzoyl-β-D-xylofuranosyl) -5-ethyluracil of formula (C) and 30 ml of pyridine,
Cool with ice water. While stirring, 1.24 g (10.8 mmol) of mesyl chloride was added dropwise, and the mixture was further stirred at 0 ° C. for 3 days.
React for time. After completion of the mesylation reaction, treatments such as distillation and extraction are performed to give 1- (2-deoxy-3-mesyl-5-
1.98 g of benzoyl-β-D-xylofuranosyl) -5-ethyluracil was obtained.

上述の様にして得た1−(2−デオキシ−3−メシル−
5−ベンゾイル−β−D−キシロフラノシル)−5−エ
チルウラシル1.9g(4.4ミリモル)、ジメチルホルムア
ミド50ml、ソジウムアジド470mg(7.2ミリモル)および
水6mlを仕込み、100℃の温度で3時間反応を行う。反応
終了後、減圧下に蒸留し、残さをシリカゲルクロマトグ
ラフィー(クロロホルム:メタノール=95:5)で精製
し、標記化合物1.27gを得た。
1- (2-deoxy-3-mesyl-obtained as described above
5-Benzoyl-β-D-xylofuranosyl) -5-ethyluracil 1.9 g (4.4 mmol), dimethylformamide 50 ml, sodium azide 470 mg (7.2 mmol) and water 6 ml are charged and the reaction is carried out at a temperature of 100 ° C. for 3 hours. After completion of the reaction, the residue was distilled under reduced pressure, and the residue was purified by silica gel chromatography (chloroform: methanol = 95: 5) to obtain 1.27 g of the title compound.

収率:87.3%1 H-NMR(CDCl3) δppm:0.95(3H,t,J=7.7Hz),2.04〜2.29(2H,m),2.4
8(2H,q,J=7.7Hz),4.08〜4.79(4H,m),6.15(1H,t,J
=6.6Hz),7.13(1H,S),7.40〜8.08(5H,m),9.31(1
H,brS)。
Yield: 87.3% 1 H-NMR (CDCl 3 ) δppm: 0.95 (3H, t, J = 7.7Hz), 2.04 to 2.29 (2H, m), 2.4
8 (2H, q, J = 7.7Hz), 4.08 to 4.79 (4H, m), 6.15 (1H, t, J
= 6.6Hz), 7.13 (1H, S), 7.40 to 8.08 (5H, m), 9.31 (1
H, brS).

参考例4 1−(2−デオキシ−3−アジド−β−D−リボフラノ
シル−5−エチルウラシル((CS-85)[(A)]の合
成 フラスコに式(B)の1−(2−デオキシ−3−アジド
−5−ベンゾイル−β−D−リボフラノシル)−5−エ
チルウラシル830mg、メタノール20mlおよび1N−ソジウ
ムメチラートのメタノール溶媒2.2ml(2.2ミリモル)を
仕込み、撹拌しながら室温下で3.5時間反応を行う。反
応終了後、イオン交換樹脂(Amberlist15)で中和して
から濾過し、濾液を減圧下に濃縮し、残さをシリカゲル
クロマトグラフィー(クロロホルム:メタノール=95.
5)で精製することにより、標記化合物560mgを得た。収
率:92.4%1 H-NMR(d6-DMSO) δppm:1.06(3H,t,J=7.5Hz),2.09〜2.55(4H,m),3.6
7〜3.89(3H,m),4.41(1H,q,J=6.2Hz),5.18(1H,t,J
=48Hz),6.13(1H,t,J=6.4Hz),7.67(1H,S),11.19
(1H,S)。
Reference Example 4 Synthesis of 1- (2-deoxy-3-azido-β-D-ribofuranosyl-5-ethyluracil ((CS-85) [(A)]] 1- (2-deoxy of the formula (B) was added to a flask. 830 mg of -3-azido-5-benzoyl-β-D-ribofuranosyl) -5-ethyluracil, 20 ml of methanol and 2.2 ml (2.2 mmol) of a methanol solvent for 1N-sodium methylate were charged, and the mixture was stirred at room temperature to obtain 3.5. After the reaction is completed, the reaction mixture is neutralized with an ion exchange resin (Amberlist15) and then filtered, the filtrate is concentrated under reduced pressure, and the residue is subjected to silica gel chromatography (chloroform: methanol = 95.
By purification in 5), 560 mg of the title compound was obtained. Yield: 92.4% 1 H-NMR (d 6 -DMSO) δppm: 1.06 (3H, t, J = 7.5Hz), 2.09 to 2.55 (4H, m), 3.6
7 to 3.89 (3H, m), 4.41 (1H, q, J = 6.2Hz), 5.18 (1H, t, J
= 48Hz), 6.13 (1H, t, J = 6.4Hz), 7.67 (1H, S), 11.19
(1H, S).

Claims (1)

【特許請求の範囲】[Claims] 【請求項1】下記式(1) 式中、R1は水素原子、水酸基又は を示す で表されるウラシル誘導体。1. The following formula (1) In the formula, R1 is a hydrogen atom, a hydroxyl group or A uracil derivative represented by.
JP15223988A 1988-06-22 1988-06-22 Uracil derivative Expired - Lifetime JPH07116211B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP15223988A JPH07116211B2 (en) 1988-06-22 1988-06-22 Uracil derivative

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP15223988A JPH07116211B2 (en) 1988-06-22 1988-06-22 Uracil derivative

Publications (2)

Publication Number Publication Date
JPH01319496A JPH01319496A (en) 1989-12-25
JPH07116211B2 true JPH07116211B2 (en) 1995-12-13

Family

ID=15536131

Family Applications (1)

Application Number Title Priority Date Filing Date
JP15223988A Expired - Lifetime JPH07116211B2 (en) 1988-06-22 1988-06-22 Uracil derivative

Country Status (1)

Country Link
JP (1) JPH07116211B2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2635778A1 (en) * 1988-08-26 1990-03-02 Ire Celltarg Sa NEW DERIVATIVES OF 3 (PREMIUM) AZIDO-3 (PRIME) DEOXYTHYMIDINE (AZT) ACTIVE AGAINST AIDS HIV VIRUS
WO1997006179A1 (en) * 1995-08-04 1997-02-20 Kobayashi Perfumery Co., Ltd. Process for producing azido nucleoside derivatives

Also Published As

Publication number Publication date
JPH01319496A (en) 1989-12-25

Similar Documents

Publication Publication Date Title
JP4202274B2 (en) Novel process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
JPH069602A (en) Intermediate of difluoro antiviral agent
JP3653292B2 (en) Mass production of 2 ', 3'-didehydro-3'-deoxythymidine (d4T) using 5-methyluridine
JP3042073B2 (en) Nucleoside derivative and method for producing the same
EP0638586A2 (en) Nucleoside derivatives and methods for producing them
KR910008112B1 (en) Process for the production of o2,2'-anhydor-1-(beta-d-arabino furanosyl)-thymine
KR20040031784A (en) Process for the preparation of l-ribavirin
JPH07116211B2 (en) Uracil derivative
JP3046359B2 (en) D-pentofuranose derivative and method for producing the same
JP3259191B2 (en) Synthesis of 2,2'-anhydroarabinosyl thymine derivatives
WO1996036603A1 (en) Improved process for producing 4-hydroxy-2-pyrrolidone
US20030236397A1 (en) Process for preparing beta-L-2'deoxy-thymidine
JP3128080B2 (en) Novel method for producing nucleic acid compounds
JP2666160B2 (en) 5-O-pyrimidyl-2,3-dideoxy-1-thiofuranoside derivative, method for producing the same and use
JPH083143A (en) Production of 6-aralkyl substituted pyrimidine derivative
JPH07116210B2 (en) Thymine derivative
JP2770357B2 (en) Method for producing nucleoside derivative
JPH0925289A (en) Production of 4'-thioarabinopyrimidine nucleoside
JPH0873488A (en) Production of 1-(2-deoxyribofuranoyl)pyridazinone derivative
JP2547125B2 (en) 2 ', 3'-dideoxy-2', 3'-disubstituted-nucleosides and process for their production
JP2000154197A (en) D-pentofuranose derivative and its production
JPH06263791A (en) Production of alpha-ribazole
HU198949B (en) Process for producing 5-substituted-3'azido-2',3'-dideoxyribonucleosides
JPH0762024B2 (en) Process for producing D-glucofuranose or D-xylofuranose derivative
KR20120055562A (en) Method for producing pyrazole glycoside derivatives